GGrantIndex
← Leaderboards

Pietro Genovese

Dana-Farber Cancer Inst

$5,128,749
Attributed
$6,295,875
Total exposure
4
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.2M · FY202125
$2.5M$1.9M$1.3M$625K$0
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$6,295,875 · 4

By mechanism

R01$6,046,230 · 3
R21$249,645 · 1

Top collaborators

Most similar at Dana-Farber Cancer Inst

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Engineering

Research focus

EngineeringEngraftmentToxic EffectCellsResponseSpecificityPreservationHematopoietic Stem CellsAllogenicAffectTransplantationResearch Clinical TestingMedicalPhysiologicalValidationBase EditingCell TransplantationInnovationGenotoxicityHematologyGene TherapyHomologous TransplantationImmunotoxinsHematopoietic Stem Cell Transplantation

Grant awards (12)

Chemotherapy-free cure of hemoglobin disorders through base editing$766,048
R01 · FY2025 · HL
Multiplex Epitope Editing to Enable Novel Immunotherapies for Acute Myeloid Leukemia$721,888
R01 · FY2025 · CA · contact PI
Development, Optimization and Preclinical Modeling of Hematopoietic Stem Cell Gene Editing for the Treatment of RAG1 Immunodeficiency$442,500
R01 · FY2025 · AI · contact PI
Advanced Genetic Engineering to Unravel Tumor-Specific B Cell Responses$249,645
R21 · FY2025 · CA · contact PI
Multiplex Epitope Editing to Enable Novel Immunotherapies for Acute Myeloid Leukemia$780,389
R01 · FY2024 · CA · contact PI
Chemotherapy-free cure of hemoglobin disorders through base editing$760,457
R01 · FY2024 · HL
Development, Optimization and Preclinical Modeling of Hematopoietic Stem Cell Gene Editing for the Treatment of RAG1 Immunodeficiency$442,500
R01 · FY2024 · AI · contact PI
Chemotherapy-free cure of hemoglobin disorders through base editing$807,747
R01 · FY2023 · HL
Development, Optimization and Preclinical Modeling of Hematopoietic Stem Cell Gene Editing for the Treatment of RAG1 Immunodeficiency$442,500
R01 · FY2023 · AI · contact PI
Development, Optimization and Preclinical Modeling of Hematopoietic Stem Cell Gene Editing for the Treatment of RAG1 Immunodeficiency$1
R01 · FY2023 · AI · contact PI
Development, Optimization and Preclinical Modeling of Hematopoietic Stem Cell Gene Editing for the Treatment of RAG1 Immunodeficiency$441,100
R01 · FY2022 · AI · contact PI
Development, Optimization and Preclinical Modeling of Hematopoietic Stem Cell Gene Editing for the Treatment of RAG1 Immunodeficiency$441,100
R01 · FY2021 · AI · contact PI